# Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

> **NCT04478071** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 448 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Coronavirus Infection

## Interventions

- **DRUG:** vadadustat
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04478071
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-22
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-03-25
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478071, "Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04478071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*